Your browser doesn't support javascript.
loading
Characterisation of tumour-derived microvesicles in cancer patients' blood and correlation with clinical outcome.
Menck, Kerstin; Bleckmann, Annalen; Wachter, Astrid; Hennies, Bianca; Ries, Lena; Schulz, Matthias; Balkenhol, Marko; Pukrop, Tobias; Schatlo, Bawarjan; Rost, Ulrike; Wenzel, Dirk; Klemm, Florian; Binder, Claudia.
Afiliación
  • Menck K; Department of Haematology/Medical Oncology, University Medical Centre Göttingen, Göttingen, Germany.
  • Bleckmann A; Department of Haematology/Medical Oncology, University Medical Centre Göttingen, Göttingen, Germany.
  • Wachter A; Department of Medical Statistics, University Medical Centre Göttingen, Göttingen, Germany.
  • Hennies B; Department of Medical Statistics, University Medical Centre Göttingen, Göttingen, Germany.
  • Ries L; Department of Haematology/Medical Oncology, University Medical Centre Göttingen, Göttingen, Germany.
  • Schulz M; Department of Haematology/Medical Oncology, University Medical Centre Göttingen, Göttingen, Germany.
  • Balkenhol M; Department of Haematology/Medical Oncology, University Medical Centre Göttingen, Göttingen, Germany.
  • Pukrop T; Comprehensive Cancer Centre, University Medical Centre Göttingen, Göttingen, Germany.
  • Schatlo B; Department of Haematology/Medical Oncology, University Medical Centre Göttingen, Göttingen, Germany.
  • Rost U; Department of Neurosurgery, University Medical Centre Göttingen, Göttingen, Germany.
  • Wenzel D; Institute for Organic and Biomolecular Chemistry, University of Göttingen, Göttingen, Germany.
  • Klemm F; Department of Structural Dynamics, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany.
  • Binder C; Department of Haematology/Medical Oncology, University Medical Centre Göttingen, Göttingen, Germany.
J Extracell Vesicles ; 6(1): 1340745, 2017.
Article en En | MEDLINE | ID: mdl-28804596
To evaluate whether tumour-derived microvesicles (T-MV), originating from the plasma membrane, represent suitable cancer biomarkers, we isolated MV from peripheral blood samples of cancer patients with locally advanced and/or metastatic solid tumours (n = 330, including 79 head & neck cancers, 74 lung cancers, 41 breast cancers, 28 colorectal cancers and 108 with other cancer forms) and controls (n = 103). Whole MV preparations were characterised using flow cytometry. While MV carrying the tumour-associated proteins MUC1, EGFR and EpCAM were found to be enhanced in a tumour-subtype-specific way in patients' blood, expression of the matrix metalloproteinase inducer EMMPRIN was increased independent of tumour type. Higher levels of EMMPRIN+-MV correlated significantly with poor overall survival, whereas the other markers were prognostic only in specific tumour subgroups. By combining all four tumour-associated antigens, cancer patients were separated from healthy controls with an AUC of up to 0.85. Ex vivo, whole MV preparations from cancer patients, in contrast to those of controls, induced a tumour-supporting phenotype in macrophages and increased tumour cell invasion, which was dependent on the highly glycosylated isoform of EMMPRIN. In conclusion, the detection of T-MV in whole blood, even in minor amounts, is feasible with standard techniques, proves functionally relevant and correlates with clinical outcome.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Extracell Vesicles Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Extracell Vesicles Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos